Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 7.5% – Here’s Why

by · The Markets Daily

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report)’s share price traded down 7.5% during mid-day trading on Friday . The stock traded as low as $33.06 and last traded at $33.22. 99,557 shares were traded during trading, a decline of 90% from the average session volume of 1,016,120 shares. The stock had previously closed at $35.90.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AGIO shares. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, Raymond James restated an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $56.33.

Get Our Latest Analysis on AGIO

Agios Pharmaceuticals Stock Performance

The company has a market cap of $1.96 billion, a P/E ratio of 3.03 and a beta of 0.87. The business has a 50 day moving average price of $46.56 and a two-hundred day moving average price of $45.43.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the second quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC increased its position in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the period. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the 3rd quarter worth $146,000.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Recommended Stories